近日,跨国药企强生宣布,将以146亿美元的总估值收购生物制药公司Intra-Cellular Therapies(下称“Intra-Cellular”)。这一交易金额,在近两年的生物医药并购市场上名列前茅,也是强生近年来金额最高的并购交易。 强生豪掷100多亿美元瞄准的是Intra-Cellular旗下一款药物——Caplyta(lumateperone 卢美哌隆),该药在上市后销量飞涨。 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.